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Abstract 
 
In animal and human studies, the neurotransmitter serotonin (5-HT) has been 
implicated in inhibitory control. Using functional magnetic response imaging (fMRI), the 
present study investigated the acute effects of pharmacological modulation in the 
serotonergic system on brain activations during response inhibition in healthy human 
volunteers. In all, 14 male participants received either a single oral dose of selective 
serotonin reuptake inhibitor (SSRI) escitalopram (10 mg) or placebo in a randomized 
double-blind placebo-controlled cross-over design. At the time of the expected plasma 
peak participants performed a stop change task during fMRI. Functional images were 
analyzed using Statistical Parametric Mapping software (SPM5). Escitalopram did not 
affect behavioral inhibitory performance as the main effect did not reveal significant 
differences of stop signal reaction time (SSRT). Likewise no differences were found for 
reaction time on go-trials (goRT) as well as for reaction time on trials of unsuccessful 
response inhibition (StopRespondRT). However, escitalopram was associated with 
alterations in brain activation patterns compared to placebo. Escitalopram enhanced 
brain activations in right prefrontal cortex, including right OFC, in right 
supplementary/pre motor and bilateral cingulate cortex as well as in subcortical regions 
during successful response inhibition. Also, escitalopram modulated a widespread 
network of brain regions, including anterior cingulate, right parietal cortex, right OFC, 
areas in right temporal cortex and subcortical regions during failed inhibition. During the 
go-process escitalopram increased brain activations in numerous regions like right 
anterior and posterior cingulate and in right prefrontal, parietal and temporal cortex as 
well as in subcortical areas. Our findings implicate an involvement of 5-HT in neural 
regulation of response inhibition. Moreover, this study provides evidence that 5-HT 
influences not only action restraint but also action cancellation through modulation of 
activations of brain areas. In addition, we found modulating effects of serotonin also on 
activations during failed inhibition. Especially, the anterior cingulate seems to play a 
critical role here. Results of this study support the assumption of an involvement of the 
anterior cingulate in error-detection. The results also implicate a fronto-striatal-circuitry 
for response inhibition in conjunction with serotonin. 
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Zusammenfassung 
 
Sowohl Tierstudien als auch Studien mit menschlichen Probanden belegen, dass der 
Neurotransmitter Serotonin (5-HT) eine entscheidende Rolle in der Handlungskontrolle 
spielt. Diese plazebokontrollierte, randomisierte Doppelblindstudie im cross-over Design 
beschäftigt sich mit den akuten Effekten einer pharmakologischen Modulation im 
serotonergen System in Bezug auf Handlungskontrolle. Dabei wurden Verhaltens- und 
Aktivierungsunterschiede im Gehirn während der Bearbeitung einer Stop-Change-
Aufgabe mit Hilfe von funktioneller Magnetresonaztomografie (fMRT) erfasst. 14 
männliche, gesunde Probanden erhielten eine orale Dosis von 10 mg Escitalopram oder 
Plazebo und absolvierten zum Zeitpunkt des erwarteten Plasmapeaks die Stop-
Change-Aufgabe während der fMRT-Messungen. Die funktionellen MRT-Bilder wurden 
mit der Software Statistical Parametric Mapping (SPM5) analysiert. Escitalopram 
beeinflusste weder die Reaktionszeit (GoRT) noch die Stopsignalreaktionszeit (SSRT), 
was sich darin zeigte, dass es keinen signifikanten Haupteffekt des Faktors Substanz 
gab. Auch die Reaktionszeit während des erfolglosen Stoppens wurde nicht beeinflusst. 
Im Vergleich zu Plazebo bewirkte Escitalopram jedoch Veränderungen von 
Gehirnaktivierungen. Während des Stoppens verstärkte Escitalopram Aktivierungen im 
rechten präfrontalen Cortex, einschließlich des rechten Orbitofrontalcortex, im rechten 
supplementären/prämotorischem Cortex, beidseitig im Cingulum sowie in subkortikalen 
Regionen. Auch während erfolglosen Stoppens modulierte Escitalopram ein 
weitreichendes Netzwerk von Gehirnregionen, einschließlich des vorderen Cingulums, 
des rechten parietalen und temporalen Cortex und subkortikaler Bereiche. Während des 
Go-Prozesses verstärkte Escitalopram Gehirnaktivierungen in vielen Regionen, unter 
anderem im rechten vorderen und hinteren Cingulum sowie im rechten präfrontalen, 
parietalen und temporalen Cortex und auch hier in subkortikalen Regionen. Diese 
Ergebnisse implizieren, dass Serotonin Einfluss auf die menschliche 
Handlungskontrolle nimmt. Außerdem liefert diese Studie Hinweise darauf, dass 5-HT 
nicht nur „ action restraint“, sondern auch „action cancellation“ durch Modulation von 
Gehirnaktivierungen beeinflusst. Weiterhin zeigte sich in dieser Studie, dass Serotonin 
die Gehirnaktivierungen auch während des erfolglosen Stoppens veränderte. Vor allem 
das anteriore Cingulum scheint hier eine entscheidende Rolle zu spielen. So bestärken 
unsere Ergebnisse die bestehende Annahme, dass diese Region an der Erkennung von 
Fehlern beteiligt ist. Außerdem implizieren die Ergebnisse dieser Studie die  Existenz 
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eines fronto-striatales Netzwerkes für die Vermittlung von Handlungskontrolle in 
Verbindung mit Serotonin.  
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Introduction 
 
Response inhibition is an important executive function providing control over responses 
in changing situations. It is required in many common everyday life situations, e.g. 
braking abruptly while driving a car. Whenever the environment alters unexpectedly 
people need to adapt and sudden change of behavior might be necessary if it turns out 
that the current process is inappropriate and a new and different goal of action is 
needed immediately. Stopping is the first step to undertake. Moreover, stopping is an 
extreme form of action-control resulting in the decision not to do something (Logan, 
1994).  
Response inhibition, i.e. the ability to stop a motor response after initiation, can be 
measured by using the stop signal task, a well-established paradigm to investigate 
inhibitory function in laboratory settings (Logan, 1994). The stop signal task consists of 
a computerized choice reaction time task in which subjects execute a simple motor 
response. Two kinds of trials are required in the procedure: to respond to two different 
go-signals, i.e. either circle or triangle (go-task) and on the other hand to withhold the 
execution of the motor response when the go-signal is followed by a stop-signal (stop-
task). The success to inhibit the response to the original go-signal depends upon the 
delay between go-signal and stop-signal (stop-signal delay) as the probability for 
successful stopping increases the sooner the stop-signal follows the go-signal. Key 
measure to characterize response inhibition is the stop signal reaction time (SSRT), the 
time it takes to stop the motor response. Stop signal reaction time achieves times 
between 200 – 400 ms, especially young adults are able to stop in about 200 ms 
(Logan, 1994). The underlying theory for estimation of SSRT is described by the so-
called horse race model (Logan, 1994; see Figure 1). According to this model there are 
two critical processes (go-process and stop-process) operating independent of one 
another. Performance of inhibition is considered as a race between these two 
processes and whichever finishes first wins the race producing either motor response 
execution or response inhibition, respectively. Another widely used method to 
investigate response inhibition is a similar paradigm known as the go/no-go task (e.g. 
Rubia et al. 2005; Liddle et al. 2001).  
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Figure 1. The horse race model 
 
 
This task likewise requires a response following the presentation of a go-signal though, 
unlike the stop signal task, this paradigm does not consist of a stop-signal delay. The 
crucial difference between both tasks is therefore the temporal location of the stop 
signal within the motor response task. Thus, the go/no-go task measures prepotent 
responses, i.e. the ability to withhold from responding as the stop-signal is presented 
before or concurrently with the go-signal. By contrast the stop signal task measures 
inhibition of already initiated responses ensuring a higher sensitivity for inhibition of 
ongoing responses. Recently, Schacher et al. (2007) defined two kinds of response 
inhibition, namely action restraint (describing motor response inhibition before the 
response has been started) and action cancellation (describing inhibition of an ongoing 
response). Whereas action restraint is investigated via go/no-go task, action 
cancellation is measured by the stop signal task. 
Patients with several brain disorders show impairment of inhibitory control. For example, 
neurological disorders have been implicated in deficient inhibitory control: Gauggel et al. 
(2004) demonstrated deficits in response inhibition in patients suffering from 
Parkinson´s disease. Furthermore, deficits in response inhibition have been shown in 
mental disorders like attention deficit hyperactivity disorder (ADHD), obsessive 
compulsive disorder (OCD) etc. Results of a novel meta-analysis of ADHD-studies 
suggested a generalized deficit in attention more than in behavioral inhibition as core 
feature of ADHD, at least in children (Lijffijt et al. 2005; Alderson et al. 2007), but a 
recent study showed that ADHD was characterized with deficient response inhibition in 
both action restraint and action cancellation (Schacher et al. 2007). Studies with 
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patients suffering from other mental disorders like OCD, trichotillomania and borderline 
personality disorder (BPD) also indicate that impairment of response inhibition obviously 
plays an important role in the psychopathology of these disorders (Chamberlain et al. 
2006; Nigg et al. 2005).  
The cognitive deficits may be related to deficits in neurotransmitter functioning in these 
disorders. The fact that mental disorders being associated with deficient cognitive 
flexibility show abnormal serotonin (5-HT) functioning for example, leads to the 
assumption that 5-HT is also involved in response inhibition (Del-Ben et al. 2005; Rubia 
et al. 2005; Cools et al. 2008). Serotonin is one of the central monoamine 
neurotransmitters and has been implicated in the etiology and psychopathology of 
several mental disorders which are associated with cognitive deficits such as major 
depression, anxiety and impulse-control-disorders (Meltzer 1989; Chamberlain et al. 
2005; Schmitt et al. 2006; Dolan et al. 2002). Furthermore, in the treatment of right 
these disorders selective serotonin reuptake inhibitors (SSRIs), 5-HT neurotransmission 
enhancing drugs, have proven efficacy. SSRIs are considered to increase central 5-HT 
concentrations as they result in elongated serotonin availability in the synaptic cleft 
(Burke 2002; Aronson & Delgado 2004; Wade et al. 2002). Yet, it remains unclear how 
cognitive processes like response inhibition are affected by 5-HT. Further evidence for 
an involvement of 5-HT in inhibition processes comes from an animal study by Clarke 
(2007) who found a deficit in a serial discrimination reversal (SDR) task after prefrontal 
serotonin depletion. This deficit was not due to a failure to approach a previously 
unrewarded stimulus, instead it was due specifically to a failure to inhibit responding to 
the previously rewarded stimulus. Eagle et al. (2008) also found a selective impairment 
in inhibition performance in rats after serotonin depletion, but only in „waiting‟ and not in 
SSRT. She suggests „waiting‟ and SSRT to be different measures of behavioral 
inhibition. 
In contrast to the suggested involvement of 5-HT in response inhibition previous work 
rather showed that 5-HT had no effect on task performance in studies with healthy 
volunteers using the stop signal task (for a review Eagle et al. 2008; Robbins 2007; 
Chamberlain and Sahakian 2007). In a study of Chamberlain et al. (2006) response 
inhibition performance was compared in two groups, one treated with SSRI citalopram, 
another treated with SNRI atomoxetine. While inhibition of central NA reuptake 
enhanced response inhibition, SSRT remained unaffected by inhibition of central 
serotonin reuptake. Another well-established method in serotonin research is a dietary 
challenge which decreases central 5-HT, the so-called acute tryptophan depletion 
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(ATD) procedure. ATD likewise had no effect on performance in the stop signal task 
(Clark et al. 2005; Eagle et al. 2008) related this matter of fact to the different forms of 
action inhibition mentioned-above. Whereas 5-HT did not influence action cancellation, 
results of studies using the go/no-go task thus measuring action restraint clearly 
indicated influence of serotonin (see Eagle et al. 2008). 
With progress in neuroimaging techniques research also focussed on specified 
localization of brain areas linked to response inhibition. In lesion and neuroimaging 
literature several brain regions like the dorsolateral, inferior, superior, orbital and mesial 
frontal cortex, the supplementary and pre-supplementary motor area, the anterior 
cingulate gyrus, the temporal and parietal lobes as well as the basal ganglia have been 
associated with motor response inhibition (Aron et al. 2003; Aron et al. 2004; Aron and 
Poldrack 2006; Rubia et al. 2003; Eagle et al. 2008). The concrete localization of 
response inhibition still appears to be difficult. However, evidence that the right inferior 
frontal cortex (IFC) is critical for inhibiting an already initiated motor response 
accumulated in neuroimaging studies with the stop signal task since response inhibition 
consistently activated this particular region (Aron et al. 2004; Rubia et al. 2003). In a 
functional magnetic resonance imaging (fMRI) study of patients with lesions of the right 
frontal cortex the authors succeeded to show that damage to the right inferior frontal 
gyrus is crucial for response inhibition, specifically BA 45 (Aron et al. 2003). Results of a 
near-infrared spectroscopy study as well pointed to association of stopping and 
activation of right-lateralized prefrontal cortex (Böcker et al. 2006). Recent research has 
also implicated the subthalamic nucleus (STN) in response inhibition which is an 
inhibitory output structure of the basal ganglia (Aron and Poldrack 2006; Li et al. 2008). 
Aron and Poldrack (2006) suggested that response execution is inhibited by a 
hyperdirect pathway via STN, which again suppresses the basal-ganglia thalamocortical 
output. Evidence for an involvement of the basal ganglia also comes from a study with 
patients suffering from Parkinson´s disease (Gauggel et al. 2004).  
In addition, different activation patterns for successful versus failed response inhibition 
have been described. Failure to inhibit has been related to the prefrontal cortex 
including anterior cingulate and inferior parietal lobes bilateral (Rubia et al. 2003). This 
is consistent with findings of go/no-go studies implicating an involvement of the rostral 
anterior cingulate in error processing (Kiehl et al. 2000; Menon et al. 2001). However, 
this aspect was not completely confirmed by Aron and Poldrack (2006) who, as well, 
focussed additionally on processes underlying failed inhibition in their study. They found 
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an activation pattern similar to successful inhibition in right IFC and STN and putamen 
though the latter region was even more activated during successful inhibition. 
Though rarely published the go-process has been associated with activations in bilateral 
putamen and left-lateralized thalamus, STN and globus pallidus as well as left motor 
cortex and left SMA during a stop signal task (Aron and Poldrack 2006). Activations 
were observed mainly left-hemispherical consistent with right-handed response. Aron 
and Poldrack (2006) related this activation pattern to a fronto-striato-pallidal pathway. 
Using a go/no-go task Liddle et al. (2001) found activations of anterior cingulate, SMA, 
contralateral motor cortex, bilateral parietal lobe, superior temporal gyrus and 
cerebellum during go trials. 
Cognitive functions such as response inhibition are related to the prefrontal cortex 
(PFC). As reviewed above the PFC has been implicated clearly in response inhibition 
via neuroimaging techniques. This region is reached by ascending serotonergic 
projections from dorsal and median raphe nuclei localized in the brain stem (see Cools 
et al. 2008; Hornung 2003). Mental disorders such as depression, ADHD and OCD 
which have been implicated in serotonergic dysfunction have also been associated with 
abnormalities in the prefrontal cortex (for a review Drevets et al. 2008; Rubia et al. 
1999; Chamberlain et al. 2005; Clark et al. 2007). The combination of cognitive task 
performance, neuroimaging techniques and neuromodulation via drug administration 
offers a suitable possibility for further investigation of 5-HT involvement in cognitive 
processes. A well-established method to challenge the serotonergic system is the 
administration of antidepressants, especially SSRIs which increase 5-HT 
neurotransmission by blocking the reuptake of 5-HT into the presynaptic neuron (Burke 
2002; Aronson & Delgado 2004; Cools et al. 2008). So far, analysis of modulating 
effects of serotonin on brain activation during response inhibition produced inconsistent 
results. Yet, only few previous fMRI studies investigated the effects of serotonergic 
modulation on cortical activation while healthy volunteers performed an inhibition 
performance task. The above-mentioned ATD procedure has been used likewise for 
fMRI studies. Rubia et al. (2005) found that ATD did not affect inhibition performance in 
a go/no-go task, but reduced right orbitoinferior prefrontal activation (BA 47, BA 45, BA 
6) during the no-go condition by contrast with go trials and increased activations in right 
and left temporal cortices (BA 21, BA 37, BA 22). The authors conclude that these 
findings provide evidence for serotonergic modulation of right inferior prefrontal cortex 
during response inhibition. In another study also using a go/no-go task no effect of ATD 
was found on task performance as well as on cortical activations (Evers et al. 2006). In 
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a review Evers et al. (2007) analyzed the two ATD studies named above coming to the 
conclusion that ATD unlikely impairs response inhibition taking into account that the 
majority of behavioral studies did not show any effects of ATD on response inhibition. In 
a fMRI study using the go/no-go task and intravenous administration of SSRI citalopram 
researchers succeded to demonstrate modulatory effects of citalopram on inhibition. 
Citalopram enhanced activations in right lateral OFC (BA 47), DLPFC and middle 
temporal gyrus, whereas attenuations were seen in the medial orbitofrontal cortex 
(BA11) more left-hemispheric, bilateral supramarginal gyri and right superior temporal 
gyrus. By reason of these results the authors supported the involvement of 5-HT in 
response inhibition (Del-Ben et al. 2005).  
The aim of the present study was to investigate the acute effects of pharmacological 
manipulation of 5-HT on brain activation patterns during response inhibition in healthy 
volunteers. As results of previous work were inconsistent we wanted to investigate the 
effects of manipulation in the serotonergic system using the most selective SSRI 
escitalopram. Moreover, to verify response inhibition as precise as possible we chose a 
stop signal paradigm more specific than the go/no-go tasks which were used in previous 
research as mentioned above. To our knowledge, no prior study investigated 
serotonergic modulation by using a combination of performance on a stop signal task 
and pharmaco-fMRI in healthy volunteers. On the basis of the above-reviewed 
literature, showing that modulation of 5-HT did not affect SSRT in healthy volunteers, 
we hypothesized that performance of response inhibition would not be affected. 
However, we hypothesized in line with previous research with SSRIs (Del-Ben et al. 
2005) that escitalopram would modulate brain activations, especially in right PFC 
associated with response inhibition. In addition, we expected that escitalopram would 
likewise alter brain activations especially in anterior cingulate during failed inhibition.  
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Figure 2. Schematical illustration of serotonergic projections (according to Törk, 1990) 
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Methods 
 
Participants 
A total of 14 male subjects participated in the study. All of them were healthy volunteers 
at the age of 18 to 39 (mean age 23.9 years, SD 2.3) who declared to be non-smokers 
and drug-free. All participants were right-handed and had normal or corrected-to-normal 
vision and hearing. They were recruited via poster advertisement and e-mail. Their 
means and standard deviation for body weight (kg) and height (cm) are 77.5 ± 8.7 kg 
and 182 ± 8.3 cm. Nearly all of them were students though varying in the specialization. 
Participants were questioned concerning their medical and psychiatric history based on 
a health questionnaire and an interview worked out by medical staff. Also, each 
participant agreed to take blood samples for blood analysis before attendance in order 
to verify physical health. Any evidence for medical or mental disorders either acute or 
chronic led to exclusion from the study.  For safety during MRI scanning all participants 
affirmed to be free of any kind of metal, pacemaker and tattoos. On the date of the tests 
participants were not allowed to smoke, to drink alcohol, to eat chocolate, nuts or 
bananas. 
All subjects gave written informed consent after detailed information of the study, the 
procedure, the substance and possible adverse events of the drug and MRI scanning. 
They were paid for study participation approximately 20 Euros per hour. The 
participants were allowed to quit the experiment at any time. All participants finished the 
trial though. The study was approved by the Ethics Committee of RWTH Aachen 
University and the National Institute for pharmaceutical and medical products (BfArM).  
 
Design and procedure 
The study was performed as a randomized double-blind cross-over design with two 
treatment levels (placebo, 10 mg escitalopram [Cipralex®]) as a single oral dose. 14 
participants received on the date of the trial a single oral dose of either 10 mg 
escitalopram or placebo, half of them receiving the drug in the first session and placebo 
in the second one, the other half vice versa. Each administration was separated by a 
washout period of seven days. The blinding was kept until both testing sessions were 
finalized. 
The present study was part of a larger research project. So due to completeness the 
entire procedure of one session will be described.  
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In the following one testing day will be described as shown in Figure 3: Starting time 
varied since the beginning of MRI scanning delayed occasionally at a time period of half 
an hour. Participants arrived at our institute at 1:45 p.m. or latest at 2:15 p.m. They were 
weighed and measured as well as blood pressure and heart rate were taken. They got a 
permanent intravenous cannula and a first baseline blood sample was taken directly. 
According to starting time administration of the drug (either escitalopram or placebo) 
was performed at 2:00 p.m. or 2:30 p.m. Afterwards participants started to complete 
several personality questionnaires which will not be described in detail as they are not 
objective of this study. One hour after drug-intake another blood sample was taken 
likewise two hours and twenty minutes after administration. Data of blood parameters 
will be analyzed separately, too. Then participants practised the stop change task as a 
start outside the MRI scanner. Three hours after drug-intake subjects started to 
accomplish the stop change task as this is, respectively, the point in time of mean 
maximal plasma concentration of escitalopram (Sogaard et al. 2005). At the same time 
functional neuroimaging via MRI scanning of the brain was performed. The participants 
took two sessions of the stop change task. Each session lasted 18 minutes in between 
a short break was offered. In a final step an anatomic scan for 9 minutes was made. At 
the end of a testing day the last blood sample as well as blood pressure and heart rate 
were taken. Also participants were asked to evaluate if they got either verum or placebo 
at their own opinion. One testing day lasted a total of 4.5 hours. Throughout the trial 
participants stayed at our institute and the Department of Radiology for MRI scanning. 
They were monitored continuously with regards to any adverse events. All participants 
completed the study.  
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Figure 3. The test procedure 
 
 
Escitalopram 
Escitalopram (Figure 4) is a selective serotonin reuptake inhibitor (SSRI) with high 
affinity and the greatest selectivity tested so far for the human 5-HT transporter. 
Escitalopram is the S-enantiomer of SSRI citalopram since pharmacological studies 
showed that the therapeutic activity of citalopram resides in the S-enantiomer (Burke 
2002). It is indicated for the treatment of major depression and anxiety disorders (Burke 
2002). Following oral administration escitalopram is rapidly absorbed, maximal plasma 
concentrations are achieved approximately 3 - 4 h after drug-intake (Sogaard et al. 
2005). It exhibits linear and dose-proportional pharmacokinetics with mainly hepatic 
biotransformation and shows a plasma elimination half-life (t ½) of 27 - 33 h consistent 
with once-daily dosing (Rao 2007). Steady state plasma concentrations are reached 
within approximately one week with once-daily administration of 10 -20 mg, the 
commonly used dose (Aronson and Delgado 2004). Compared to placebo, first 
improvements of symptoms are seen within 1−2 weeks after commencing treatment 
verified on depression rating scales (Burke 2002). Escitalopram is generally well 
tolerated in clinical trials due to the fact that its high affinity and selectivity for the 5-HT 
transporter results in no or little affinity to other receptors and therefore less adverse 
events. However, most commonly observed side-effects associated with the substance 
(incidence of approximately 5% or greater or at a greater rate than placebo) are nausea, 
insomnia, ejaculation disorder, diarrhoea, dry mouth and somnolence whereas only 
nausea occurred in over 10% of escitalopram-treated patients (Burke 2002). 
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For our study we used the drug Cipralex and placebo manufactured by Lundbeck. 
 
        Figure 4. Chemical structure of escitalopram 
 
 
Stop change paradigm 
The stop change task is a computer based test developed to evaluate response 
inhibition and response re-engagement. As the present study just focuses on inhibition 
the change task will be described for reasons of completeness though analyzed 
separately. 
The stop change paradigm (see Figure 5) was composed of four different trial types: the 
go-trials, stop-trials, change-trials and null events. The first three trial types will be 
referred to as stimulus trials. The duration of the stimulus trials was 3350 ms whereas 
the null events either lasted 2800 or 3350 ms. 
The go-trials required to execute a simple motor response following the presentation of 
two stimuli. They made up 70% of the stimulus trials and were part of a simple choice 
reaction time task in which participants had to discriminate a black circle and a black 
triangle on a computer monitor. Depending on which of the two go-stimuli was 
presented, participants had to respond either with a left or right key press using index 
and ring fingers of their right hand. On stop-trials (15% of stimulus trials) the choice 
reaction time task was followed by an occasionally and unpredictable auditory stop 
signal (a 1000 Hz tone of 500 ms duration) after a variable delay (stimulus onset 
asynchrony, SOA). It signalled the participants to inhibit the execution of their response 
to the choice reaction time task. In another 15% of the stimulus trials a change signal (a 
400 Hz tone of 500 ms duration) likewise was presented after a variable delay. This 
signal indicated that participants should now inhibit their response to the choice reaction 
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time task and press instead the middle of the three response buttons with their right 
middle finger. 
The stop signal delay (stop-SOA) and the change signal delay (change-SOA) were fixed 
by a staircase-tracking algorithm (Kaernbach, 1991) that adapted to the response rate. 
The stop-SOA and the change-SOA were adjusted independently that way participants 
reached an inhibition rate of approximately 50% (stop condition) or a change rate of 
likewise approximately 50% (change condition). Setting an accuracy of 50% ensures 
equal probability for stopping as well as for not stopping, i.e. the probability of stopping 
is neither overestimated nor underestimated. The staircase-tracking algorithm worked 
as follows: Initially the stop-SOA and the change-SOA were set at 250 ms. Depending 
on the success in response inhibition on stop-trials or success in changing on change-
trials the SOA was increased by 50 ms in the following stop-trial or change-trial. Thus, a 
greater difficulty for participants to inhibit or change their responses was produced. If, 
however, participants failed to inhibit or change their response, the SOA was decreased 
by 50 ms in the next stop- or change-trial, enhancing the chance of successful inhibition 
or changing. This tracking procedure provides a possibility to estimate inhibition 
performance, the stop signal reaction time (SSRT), which is relatively stable against any 
violations of independence between go- and stop-processes. Moreover, the individual 
adjustment of stop signal delay and change signal delay allows maintaining a high level 
of difficulty in inhibition and at the same time homogeneity across subjects by making 
the participants work in the edge of their inhibitory capacity. 
Participants trained the paradigm as follows: Four blocks, containing 44 trials each, 
were performed to introduce the different types of trials. Participants were instructed to 
respond as fast as possible while keeping a high level of correctness. They were briefed 
not to slow down and wait for a possible stop or change signal thus delaying their 
response, but then to try hard to withhold the response after hearing a stop signal or 
change the response after the corresponding change signal. To prevent them from 
developing a strategy participants were told that they would not be able to withhold the 
response at all times since the computer would adapt to their results aiming for a 
success rate of 50%.  
The participants took two sessions of the stop change task with 308 trials each (196 go-
trials, 42 stop-trials, 42 change-trials and 28 null events) while fMRI scanning. The 
visual stimuli were presented via a head-mounted video display designed to meet MR 
requirements. If necessary vision was adjusted to normal by placing correcting lenses in 
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the goggles. The auditory stimuli were presented via headphones at an individually 
adapted volume-level which was able to penetrate MRI scanner noise. 
 
 
 
 
                              Figure 5. The stop change paradigm 
 
 
fMRI acquisitation 
MR images of the subjects´ brains were acquired at the Department of Radiology of the 
University Hospital of RWTH Aachen University using a 1.5 Tesla Philips Gyroscan NT 
with standard head coil and foam padding to restrict movements. Axial multislice T2-
weighted images were obtained with a gradient-echo planar imaging sequence (TE = 50 
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ms; TR = 2800 ms; 64 x 64 matrix; flip angle = 90°; 30 slices, 3.4375 x 3.4375 mm in-
plane resolution; slice thickness 3.75 mm; no gap; voxelsize 3.75 x 3.75 x 3.75) 
covering the entire brain. The scanning session consisted of two subsessions, each 
starting with 10 dummy scans that were not recorded for data analysis allowing tissue to 
reach steady state magnetization. During each subsession 380 volumes were acquired. 
Inherent to the stop change paradigm is the fact that the experimenter does not know in 
advance on which of the stop- and change-trials the participant will successfully inhibit 
or change the initiated response and on which he will fail. However, to ensure an 
optimized scanning of the hemodynamic response in all brain slices for all four critical 
stop- and change-conditions, namely StopInhibit, StopRespond, StopChange and 
ChangeRespond, the experiment was programmed the following way: The TR-time was 
subdivided into four equally sized so called TR-classes (TR1: 0-700, TR2: 700-1400, 
TR3: 1400-2100, TR4: 2100-2800). An adaptive TR-class tracking algorithm used from 
the beginning of the second subsession guaranteed that approximately the same 
proportion of StopInhibits, StopResponds, StopChanges and ChangeResponds fell into 
each TR-class. This was achieved by taking the probable answer of participants into 
account (on the basis of whether the stop-or change-SOA was increased or decreased 
in the next stop- or change-trial) and so by altering the original onset of the respective 
trial. 
 
Statistics 
Behavioral data 
Behavioral data were analyzed using Statistical Package for the Social Sciences 
(SPSS) Version 16.  
Following parameters of the stop change paradigm were determined for this part of the 
study: goRT for correctly answered go-trials and stop-SOA for stop signal delay. On the 
basis of these parameters SSRT for successful inhibited responses was estimated via 
subtracting the delay of the mean reaction time of go-trials (SSRT = mean goRT minus 
stop-SOA). Also, we determined StopRespondRT for trials of unsuccessful inhibition but 
correctly answered to the original choice reaction time task. 
To verify the working of the tracking algorithm the rate of successful stopping was 
determined which had to range between 40% and 60%. 
A one factorial analysis of variance (ANOVA) for repeated measures with a repeated 
measurement factor “substance” (10 mg escitalopram versus placebo) was performed 
to analyze the dependent variables SSRT, RT on go-trials and RT on StopRespond. All 
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data were screened for outliners. Since few, though slight, outliners were detected, 
results were compared once outliners excluded, once included. Due to the fact that no 
change of significance was seen on statistical level and no changes of activations were 
found in fMRI data, we decided to keep all 14 participants in our analysis supporting the 
maximal number of participants for further analysis of fMRI data. 
 
fMRI data 
Functional images were analyzed using Statistical Parametric Mapping software (SPM5; 
Wellcome Department of Cognitive Neurology, London, UK; 
http://www.fil.ion.ucl.ac.uk/spm/).  
Preprocessing procedures included realignment to correct for motion artefacts using the 
very first scan as a reference. Images were normalized into standard stereotactic space 
using Montreal Neurological Institute (MNI) templates. Finally images were spatially 
smoothed using a Gaussian kernel of 8 mm full-width at half maximum (FWHM) to 
facilitate intersubject averaging. No participant had to be excluded from further analysis 
due to movement artefacts. 
First-level analysis was performed on each subject to generate a design matrix using a 
random effect model with following events: StopInhibit, StopRespond, Go and null-
event. The hemodynamic response function was modelled to the onset of the 
responses. On second-level analysis a full factorial ANOVA with factors “substance” 
and “condition” was performed. Six contrasts were calculated using whole brain analysis 
to asses the effect of escitalopram: StopInhibitescitalopram > Stopinhibitplacebo, 
StopInhibitplacebo > Stopinhibitescitalopram and StopRespondescitalopram > StopRespondplacebo, 
StopRespondplacebo > StopRespondescitalopram and Goescitalopram > Gopacebo, Goplacebo > 
Goescitalopram. Statistical maps were thresholded at p < 0.005 uncorrected with cluster 
sizes of 5 or more voxels. In addition, another complex contrast which is of interest on 
account of its repeated presence in the literature was calcultated: StopInhibit minus 
Goescitalopram > StopInhibit minus Goplacebo and, vice versa, StopInhibit minus Goplacebo > 
StopInhibit minus Goescitalopram. Statistical maps were thresholded at p < 0.01 
uncorrected with cluster sizes of 5 or more voxels for this contrast. 
 
 
 
 
19 
 
Results 
 
Behavioral data 
Means  SD for goRT are 465.06  168.09 ms for placebo and 399.96  63.81 ms for 
escitalopram (Figure 6). Means  SD for SSRT are 229.81  54.21 ms for placebo and 
246.52  45.34 ms for escitalopram (Figure 6). Means  SD for  StopRespondRT are 
431.59  148.82 ms for placebo and 380.50  35.16 ms for escitalopram (Figure 6). 
Analysis of variance revealed for the main effect of factor “substance” no significant 
differences for goRT (F = 2.2, df = 1, p = .162) and SSRT (F = 1.052, df = 1, p = .324) 
and StopRespond RT (F = 1.828, df = 1, p = .199) which means that results with 
escitalopram did not differ from placebo results.  
 
 
                  Figure 6.  Performance on the stop signal task following escitalopram and placebo 
 
 
fMRI data 
Response Inhibition 
Results of brain activations during response inhibition are represented in Table 1. 
Successful response inhibition for StopInhibitescitalopram > StopInhibitplacebo was 
associated with increased activations at p < 0.005 uncorrected in right orbito frontal 
cortex (OFC) (BA 10/11, see figure 8) as well as right middle frontal gyrus (BA 8) and 
right cingulate (BA 24). Left lateralized activations were seen in cingulate (BA 31), also 
anterior cingulate (BA 25), precuneus (BA 7) and middle temporal cortex (BA 21). 
20 
 
Although activations were bilaterally located the focus was right-lateralized. Brain 
activations for StopInhibitescitalopram > StopInhibitplacebo are shown in Figure 7. In the 
contrary condition, response inhibition for StopInhibitplacebo > StopInhibitescitalopram brain 
activations were found bilaterally in the superior frontal gyrus (BA 8).  
 
 
Table 1. Brain activations during successful response inhibition 
Region    BA Hemisphere x y z Z-Score 
       
a) Escitalopram > Placebo       
Cingulate gyrus 31 left -20 -57 25 3.48 
Parietal lobe precuneus 7 left -16 -68 29 3.08 
Medial frontal gyrus 10/11 right 8 42 -12 3.43 
Middle temporal gyrus 21 left -48 -8 -13 3.32 
Anterior cingulate 25 left -4 7 -10 3.24 
Superior/middle frontal gyrus 8 right 24 14 40 3.15 
Cingulate gyrus 24 right 16 -1 48 3.14 
       
b) Placebo > Escitalopram       
Superior frontal gyrus 8 right 8 38 53 3.02 
Superior frontal gyrus 8 left -4 42 53 2.95 
       
Statistical maps were thresholded at p < 0.005 uncorrected. 
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Figure 7. Brain activations during successful response inhibition for escitalopram > placebo 
 
 
       
 
 
Figure 8. Enhanced brain activation in BA 10/11during response inhibition with escitalopram 
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Response inhibition minus go 
Brain activations for StopInhibit minus Goescitalopram > StopInhibit minus Goplacebo  are 
listed in Table 2 and presented in Figure 9. The contrast StopInhibit minus Goescitalopram > 
StopInhibit minus Goplacebo at p < 0.01 uncorrected was associated with significant 
activations in bilateral parietal lobe (BA 7), left hemispheric insula (BA 13), claustrum 
(BA 13), lentiform nucleus and caudate. Also activations were found in right-lateralized 
posterior cingulate (BA 29), thalamus, middle frontal gyrus (BA 6) as well as red 
nucleus. The contrast StopInhibit minus Goplacebo > StopInhibit minus Goescitalopram 
showed activations in right thalamus and left cingulate (BA 31).  
 
 
Table 2. Brain activations for the contrast StopInhibit minus Go  
 
Region    BA Hemisphere x y Z Z-Score 
       
a) Escitalopram > Placebo       
Parietal lobe precuneus 7 left -20 -68 48 4,06 
Superior parietal lobule 7 right 28 -63 51 3,23 
Insula 13 left -40 8 14 3,22 
Claustrum 13 left -28 9 18 3,10 
Posterior cingulate 29 right 12 -42 17 2,99 
Thalamus  right 8 -35 9 2,74 
Thalamus  right 28 -31 2 2,98 
Lentiform nucleus Putamen  left -24 -7 19 2,98 
Caudate  left -20 -10 26 2,75 
Insula 13 left -32 -6 26 2,66 
Middle frontal gyrus 6 right 24 -6 41 2,87 
Frontal lobe sub-gyral 6 right 20 -1 55 2,5 
Midbrain red nucleus  right 4 -27 -5 2,73 
Claustrum  left -24 20 14 2,72 
       
b) Placebo > Escitalopram       
Cingulate gyrus 31 left -20 -30 31 3,08 
Thalamus  right 8 -4 4 2,93 
       
Statistical maps were thresholded at p < 0.01 uncorrerected. 
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         Figure 9. Enhanced brain activations by escitalopram compared to placebo for the contrast    
         Stopinhibit minus Go 
 
 
Failed response inhibition 
Results of brain activations during failed response inhibition are represented in Table 3. 
StopRespondescitalopram > StopRespondplacebo significantly activated      (p < 0.005 
uncorrected) right somatosensory cortex (BA 3), right primary motor cortex (BA 4), right 
cingulate (BA 24/32), right middle and superior temporal gyrus (BA 21, BA 38), right 
medial frontal gyrus (BA 25) as well as right putamen. Left-hemispherical activations 
were observed in the parahippocampal gyrus, caudate head and in the temporal cortex 
(BA 37). Also left auditory cortex (BA 19, BA 22) was activated. Brain activations of this 
contrast are demonstrated in Figure 10. There were no activations found for the reverse 
condition placebo > escitalopram.  
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 Table 3. Brain activations during failed inhibition 
Region BA Hemisphere x y Z Z-Score 
       
a) Escitalopram > Placebo       
Postcentral gyrus 3 right 51 -17 56 4,28 
Parahippocampal gyrus 35 left -24 -24 -22 3,86 
Cingulate gyrus 24/32 right 16 17 25 3,81 
Middle temporal gyrus 21 right 48 2 -34 3,78 
Middle/superior temporal 
gyrus 
19/22 left -32 -58 10 3,73 
Caudate head  left -8 19 -4 3,68 
Precentral gyrus 4 right 20 -21 49 3,57 
Superior temporal gyrus 21/38 right 48 3 -10 3,36 
Medial frontal gyrus 25 right 12 7 -14 3,11 
Lentiform nucleus, Putamen  right 16 7 -7 2,72 
Putamen  right 16 7 -7 2,72 
Middle temporal gyrus 21 left -51 -5 -13 3,09 
Fusiforme gyrus 37 left -48 -51 -11 2,87 
 
 No increased activations in the placebo condition compared with escitalopram were found. 
 Statistical maps were thresholded at p < 0.005 uncorrected; listing of strongest activations 
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       Figure 10. Brain activations during failed inhibition for escitalopram > placebo 
 
 
Going 
Brain activations for go-trials are listed in Table 4. Enhanced activations on go-trials for 
Goescitalopram > Goplacebo were observed at p < 0.005 uncorrected obviously right-
lateralized: Insula (BA 13), anterior and posterior cingulate (BA 30, BA 32), superior 
temporal gyrus (BA 38, BA 13), postcentral gyrus (BA 1) and in the middle frontal gyrus 
(BA 9). Left-lateralized activations were located in the subthalamic nucleus and middle 
temporal gyrus (BA 21). Brain activations during going for escitalopram > placebo are 
shown in Figure 11. Go-trials for Goplacebo > Goescitalopram were as well associated with a 
right-lateralized network of brain regions in the middle frontal gyrus (BA 10, BA 11, BA 
6), medial frontal cortex including supplementary motor cortex and precentral gyrus (BA 
6), superior frontal gyrus (BA 8, BA 10), caudate head, precuneus (BA 7) and middle 
temporal gyrus (BA 21). Also left medial and middle frontal cortex (BA 6) as well as 
superior frontal gyrus (BA 10) showed activations.  
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Table 4. Brain activations during going 
Region BA Hemisphere x y z Z-Score 
       
a) Escitalopram > Placebo       
Insula 13 right 44 -7 8 4,02 
Subthalamic nucleus  left -8 -12 -3 3,53 
Posterior cingulate 30 right 12 -54 6 3,44 
Superior temporal gyrus/sub-gyral 38/13 right 44 3 -10 3,37 
Anterior cingulate 10 right 12 34 -12 3,28 
Middle temporal gyrus 21 left -44 -1 -27 3,15 
Postcentral gyrus 1 right 67 -14 27 3,14 
Anterior cingulate 32 right 4 43 -2 3,09 
Middle frontal gyrus 9 right 28 32 21 2,85 
       
b) Placebo > Escitalopram       
Middle frontal gyrus 10/11 right 36 54 -9 4,79 
Medial frontal gyrus 6 left -8 -17 56 4,04 
Medial frontal gyrus 6 right 12 -17 56 3,92 
Superior frontal gyrus 10 right 36 56 23 3,70 
Superior frontal gyrus 8 right 20 33 46 3,65 
Middle frontal gyrus 6 right 32 2 37 3,54 
Middle frontal gyrus 47 left -36 39 -5 3,49 
Caudate head  right 16 27 -1 3,43 
Parietal lobe precuneus 7 right 16 -79 48 3,41 
Middle temporal gyrus 21 right 59 -28 -15 3,15 
Caudate  right 24 -38 13 3,40 
Superior frontal gyrus 10 left -36 48 23 3,11 
Precentral gyrus 6 right 55 -3 26 2,81 
       
Statistical maps were thresholded at p < 0.005 uncorerrected; listing of strongest activations. 
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       Figure 11. Brain activations during going for escitalopram > placebo 
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Discussion 
 
The present study investigated the acute effects of pharmacological modulation of 5-HT 
on brain activations during response inhibition in healthy volunteers. 14 male 
participants performed a stop signal task after oral administration of SSRI escitalopram. 
Escitalopram did not affect inhibitory performance as the main effect did not reveal 
significant differences of SSRT, but was associated with alterations in brain activation 
patterns compared to placebo. Escitalopram enhanced brain activation in right 
prefrontal cortex, including right OFC, in right supplementary / premotor and bilateral 
cingulate cortex as well as in subcortical regions during response inhibition. In the 
condition of failed stopping escitalopram activated a widespread network of brain 
regions, including anterior cingulated, right parietal cortex, right OFC, areas in right 
temporal cortex and subcortical regions. During the go-process escitalopram increased 
activations in numerous regions like right anterior and posterior cingulate and in right 
prefrontal, parietal and temporal cortex as well as in subcortical areas.  
The lack of effects of escitalopram on task performance is in line with various studies 
that as well did not find effects of 5-HT modulation on response inhibition using either a 
stop signal task (Clark et al. 2005, Chamberlain et al. 2006) or a go/no-go task (Del-Ben 
et al. 2005; Evers et al. 2006; Rubia et al. 2005). The stop signal task and go/no-go task 
differ in design of paradigm and, as a result, in determination of inhibitory performance. 
However, the lack of effects of 5-HT on task performance seems to be steady across 
paradigms. These studies also used different methods of intervention in the 5-HT 
system. The fact that indeed none succeeded to demonstrate an effect on inhibitory 
performance implicates that modulation of the serotonergic system has no effect on 
response inhibition at least not reflected in task performance. 
Focus of our interests was the role of escitalopram. Yet, for reasons of control we also 
reviewed fMRI data of response inhibition in the placebo condition. During the stop 
process we found activated areas that have been related consistently to response 
inhibition, including right lateral IFC, right DLPFC, the right supplementary motor area 
and temporal regions (data not presented here). These brain areas have been 
associated with response inhibition in multiple fMRI studies and they are considered as 
relevant brain regions for response inhibition (Aron et al. 2003; Aron et al. 2004; Aron 
and Poldrack, 2006; Rubia et al. 2003). Since we were able to reproduce these crucial 
stopping areas we assumed that our study measured stopping performance, 
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respectively. Furthermore, we therefore assumed that alterations of brain activation 
patterns were induced by escitalopram. 
Our findings of enhanced brain activations in right prefrontal cortex, including right OFC 
with escitalopram during response inhibition are consistent with results of previous 
research (Del-Ben et al. 2005; Rubia et al. 2005). The OFC has been implicated in 
mediation of inhibitory control (Rubia et al. 2005). Eagle et al. (2008) also suggested 
that the OFC is involved in the stopping process by mediating stopping via an 
orbitofrontal-DMStr-pathway. However, there are also differences to results of Del-Ben 
et al. (2005) who found increased activation of right lateral OFC (BA 47) and 
dorsolateral PFC (BA 9), whereas attenuations were seen in OFC (BA 11), an area 
which showed increased activation in our study. Nevertheless, Del-Ben et al. saw 
medial OFC activation related to response inhibition though not enhanced by 
citalopram. This might be due to task- and design related differences. Del-Ben et al. 
used a go/no-go task while we used a stop signal paradigm. The go/no-go task does not 
consist of a stop signal delay and measures prepotent responses, i.e. action restraint, 
consequently. The stop signal task is more precise in measuring response inhibition of 
ongoing processes, i.e. action cancellation. Because of the different paradigms used in 
both studies there were also designed different contrasts. Consequently, one can 
expect differing results. Del-Ben et al. only reported a more complex no-go minus go 
contrast, whereas the contrast StopInhibitescitalopram > StopInhibitplacebo that we generated 
was not investigated in their study. We only saw increased activations in right medial 
OFC in this condition. However, in our similar contrast StopInhibit minus Goescitalopram > 
StopInhibit minus Goplacebo we found activation patterns particularly in subcortical 
regions which is consistent with previous findings relating subcortical regions to 
response inhibition (Aron and Poldrack 2006; Li et al. 2008; Del-Ben et al. 2005; Kelly et 
al. 2004). The OFC is strongly connected to subcortical regions (Alexander et al. 1990; 
Cools et al. 2008). The study of Del-Ben et al. (2005) and our study also differ in the 
substance used for pharmacological modulation and its admisitration route: Intravenous 
administration of SSRI citalopram used by Del-Ben at al. versus the oral administration 
of escitalopram we used. Although both citalopram and escitalopram belong to the 
same group of pharmaceutical substance, escitalopram still owns more selectivity for 
the human 5-HT transporter. The different way of drug administration also could be a 
reason for the differing results. We decided to investigate acute administration of SSRI 
escitalopram which produces extended 5-HT availability in the synaptic cleft by blocking 
the human 5-HT transporter. However, Rubia et al. (2005) found a similar activation 
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pattern like Del-Ben et al. (2005). Rubia et al. likewise used a go/no-go task but ATD 
procedure for 5-HT modulation. This method interferes in the serotonergic system by 
producing a decrease of central 5-HT via decreased tryptophan availability in the brain. 
According to Cools et al. (2008) this reduction is mild and only transient though. 
Actually, Evers et al. (2006) did not see any effect of ATD on brain activation in a go/no-
go task ascribing this matter of fact likewise to differences in the paradigma and design. 
However, our findings are partly consistent with a study by Anderson et al. (2002) using 
m- chlorophenylpiperazine (mCPP) for modulation. They demonstrated increased brain 
activations associated with mCPP in a no-go minus go contrast in right ventral lateral 
PFC, but also in the caudate, a region showing activation enhancement in our study in 
the corresponding condition StopInhibit minus Goescitalopram > StopInhibit minus Goplacebo 
as well. The caudate is reached by ascending sertonergic projections from the raphe 
nuclei (Feldman et al. 1997) which could be a reason for increased activations in this 
region with escitalopram. However, recent findings suggested the caudate playing a role 
in the controlled execution of movement. Li et al. (2008) found greater activity in the 
caudate in association with short SSRT compared to long SSRT and this activity also 
correlated with medial prefrontal activity. Just like Li et al. we would suppose that more 
research is needed to specify the definite role of the caudate. Consistent with findings in 
previous literature we found activations in insula and thalamus (Aron and Poldrack 
2006; Del-Ben et al. 2005; Kelly et al. 2004). The thalamus as component of the fronto-
striato-thalamic-pathway is supposed to gate and facilitate cortically initiated 
movements (Alexander et al. 1990). However, Li et al. (2008) supposed amongst others 
that thalamus and basal ganglia might delay SSRT. The insula has been implicated in 
response selection processes under conditions of reduced preparation (Kelly et al. 
2004). But then, Anderson et al. (2002) found attenuations in right insula and thalamus 
whereas we located increased activations in right thalamus and left insula. This might 
be likewise due to task- and substance-related differences as discussed before. mCPP 
is a non-selective 5-HT ligand binding to diverse 5-HT receptors, even 2-
adrenoceptors, with greatest affinity for 5-HT2C and possibly 5-HT1B. It is therefore an 
unspecific substance for modulation of 5-HT, most notably in comparison to 
escitalopram with greatest selectivity for the serotonin transporter and for 5-HT1A 
receptors, too. For comparison of both substances one also has to keep in mind that 
mCPP is an agonist whereas escitalopram has antagonistic property. Whereas agonists 
bind a certain receptor and alter the receptors´ activity, antagonists simply bind the 
receptor without producing a response itself though blocking agonist-mediated 
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responses. Nevertheless, Völlm et al. (2006) found enhanced activations in right lateral 
OFC and left insula as well though the latter region did not remain significant after small 
volume correction. Völlm et al. used mirtazapine, an antidepressant substance blocking 
presynaptic 2-adrenic autoreceptors which leads to increased noradrenaline (NA) 
release and enhances serotonergic transmission again. Since mirtazapine blocks 5-
HT2C receptors as well, its main effects on 5-HT are mediated via postsynaptic agonistic 
action on 5-HT1A receptors. Although the authors related alterations of brain activations 
to the serotonergic effects of mirtazapine, most likely adrenergic receptor effects also 
influenced the results. Another interesting aspect is that we found enhanced activations 
in BA 24 and BA 8, areas that have been related to error detection and conflict 
monitoring and therefore they have been suggested to reflect response conflict in a 
go/no-go task (Kelly et al. 2004; Rubia et al. 2003). This might implicate a serotonergic 
influence not only on pure inhibitory control but also on other components belonging to 
response inhibition. To sum up, several studies provide evidence for 5-HT mediated 
alterations of brain activations associated with response inhibition. Mainly enhancement 
of activation in right lateral OFC was found across substances in contrast to our own 
results. These studies commonly used a go/no-go task investigating action restraint, 
though. However, all studies including our findings support a 5-HT related enhancement 
in right PFC, particularly in right OFC in general. It remains unclear why our results 
implicate an involvement of medial OFC. The medial PFC is strongly innervated by 
serotonergic projections from the rostral raphe nuclei (for review Hornung 2003; 
Feldman et al. 1997). As escitalopram is more selective than other substances used so 
far its effects might be responsible for dislocation from lateral to medial regions in the 
OFC. Our findings of increased activations of subcortical regions confirm suggestions of 
their involvement in response inhibition. The basal ganglia have been implicated in 
response inhibition in previous research (Rieger et al. 2003; Gauggel et al. 2004; Eagle 
et al. 2008; Aron and Poldrack 2006). Our results are consistent with an orbitofrontal-
striatal-circuitry that has been discussed for stopping before (Eagle et al. 2008; 
Chamberlain et al. 2006). Furthermore, we found a serotonin related modulation, most 
likely because of the numerous serotonergic projections ascending from the raphe 
nuclei to the basal ganglia (Feldman et al. 1997). Altogether, our results clearly support 
an influence of serotonin on response inhibition. We found 5-HT modulated activations 
of brain regions that have been associated consistently with response inhibition 
providing first evidence for an influence of 5-HT on action cancellation. 
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Our results of brain activation patterns during failed stopping are in line with Rubia et al. 
(2003) who found activations in mesial frontopolar cortex (BA 10) and anterior cingulate 
cortex (ACC) (BA 24/32). Rubia et al. likewise used a stop signal task though the study 
was not designed to investigate any kind of modulation of neurotransmission. We found 
increased activation in BA 24/32 in our study as well. Rubia et al. supposed that this 
region might be implicated in error detection. This is consistent with observations made 
in two go/no-go studies, both implicating that the rostral anterior cingulate is involved in 
error processing (Kiehl et al. 2000; Menon et al. 2001). However, since the ACC has 
also been related to successful response inhibition and even to go-trials the region has 
been suggested to reflect generic attention or conflict and decision monitoring functions 
(Liddle et al. 2001; Rubia et al. 2003). Furthermore, we detected increased activation in 
medial frontopolar cortex (BA 25) which is consistent with Rubia´s assumption of an 
involvement of mesial prefrontal cortex in error detection in the context of failed 
inhibition. Kelly et al. (2004) also found activations in medial frontal lobe during a go/no-
go task which they related to the response conflict inherent in a no-go trial. Thus, our 
findings might support the suggestion of a neural network of mesial prefrontal cortex, 
including ACC for error detection. 5-HT might even lead to activation enhancement 
possibly by reason of the serotonergic projections reaching this area. However, bearing 
in mind that our results only represent enhanced activations with escitalopram they 
cannot be discussed in that way without considering the modulating effects of the drug. 
Aron and Poldrack (2006) found activations in right lateral IFC and STN similar to 
activation patterns during successful response inhibition but also they did not 
investigate effects of manipulation of any neurotransmission. According to the horse 
race model (Logan, 1994) stop-process and failed stopping should function similar but 
with different results, i.e. either successful or postponed and therefore unsuccessful 
inhibition. The regions Aron and Poldrack found did not show enhanced activations in 
our study. However, we found increased activations in medial prefrontal cortex and 
cingulate as well as in subcortical regions in both, successful and failed inhibition. This 
matter of fact would confirm a similar network for successful and failed inhibition. Our 
pharmacological modulation might have produced activation patterns deviating from the 
regions Aron and Poldrack (2006) detected. Whereas we found increased activation in 
right putamen associated with escitalopram, Aron and Poldrack found by substracting 
StopInhibit minus StopRespond that there was significantly more activation within 
putamen for StopInhibit than StopRespond which they related to a slower go-process. 
Increased activation in putamen associated with escitalopram could otherwise implicate 
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a fronto-striato-pallidal-STN pathway for response inhibition which they discussed in the 
context of putamen-activation as well. The putamen is one of the input structures of the 
basal ganglia and it is reached by serotonergic projections (Alexander et al. 1990; Mink 
1996; Cools et al. 2008; Feldman et al. 1997) By taking both, results of successful and 
failed inhibition, into consideration a fronto-striato-circuitry might be suggested possibly 
in conjunction with serotonin. However, since there is no literature of failed inhibition 
combined with serotonergic modulation results are difficult to frame. Clearly, more 
research is needed not only to investigate an involvement of 5-HT in failed inhibition, but 
also to find out if unsuccessful inhibition is associated with a similar activation pattern 
like response inhibition or if the mesial frontal cortex and anterior cingulate are 
particularly responsible for failed inhibitory performance in terms of error detection.  
During the go-process we located enhanced activations mainly right-lateralized in 
insula, anterior and posterior cingulate, somatosensory, temporal and frontal cortex. Our 
results are contrary to Aron and Poldrack (2006) who found activations of motor areas 
contralateral to the response hand, including primary motor cortex, SMA, putamen and 
pallidum. The only accordance is activation of left STN which Aron and Poldrack related 
to a hyperdirect discharge before voluntary movement (Mink, 1996) but they decided 
not to go into detail. To discuss these results, again, one has to consider that our results 
only represent activations which were enhanced by escitalopram compared to placebo 
while Aron and Poldrack did not undertake any pharmacology intervention. However, 
our results are partly consistent with brain activations Liddle et al. (2001) found during a 
go/no-go task. They as well detected brain activations of anterior cingulate, superior 
temporal gyrus and in parietal lobe as well as in SMA although we only found 
activations in the latter region with placebo. In previous studies investigating 
serotonergic modulation activation patterns during the go-process were not published, 
so there is no literature to compare with. As we were able to demonstrate in our placebo 
condition of stopping that our study produced activation patterns in accordance with the 
literature, this might lead to the assumption that the differences of activations during the 
go-process are caused by our manipulation in the serotonergic system. Consistent with 
this assumption activations were seen in regions reached by the serotonergic 
projections which implicates thereby a modulating effect also in the go-process. 
However, for further considerations more research of the go-process is needed. Since 
our main focus lies on response inhibition we decided likewise not to discuss this 
further. 
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The contrasts vice versa with enhanced activations under placebo compared to 
escitalopram did not reveal many results. As the focus of our study was on effects of 
serotonin we listed them just for reasons of completeness. Yet, we decided not to go 
into detail since our contrasts with escitalopram > placebo compete with more 
interesting questions in the context of our study. 
In comparison to serotonin results of studies using pharmacological manipulation of the 
noradrenergic system showed promising effects of noradrenaline even on task 
performance in response inhibition (Chamberlain et al. 2006). The results of Völlm et al. 
(2006) who investigated the effects of mirtazapine on response inhibition also could be 
considered against the background of possibly mediated effects through the 
substance´s noradrenergic actions. Further research is clearly needed to find out if 
other central neurotransmitters influence response inhibition, perhaps even more than 
5-HT. 
 
Limitations 
A relative small sample size was used for the present study which is limiting factor 
particularly for analysis of performance data. However, compared to other studies with 
even less participants (Anderson et al. 2002; Del-Ben et al. 2005) our number of 
participants seems suitable. It is definitely necessary to replicate the acute effects of 
oral administration of escitalopram on brain activation in following studies using at best 
more significant sample sizes. Although the stop signal task is a very specific paradigm 
for measuring response inhibition, estimation of SSRT still deals with a conclusion as 
response inhibition is not measured directly but estimated via mathematical formula. We 
anticipate that response inhibition performance is measured by SSRT which is based on 
an assumption, though. Inhibiting highly selective the 5-HT transporter, escitalopram still 
holds affinity for other neurotransmitter receptors, including 5-HT1A and 5-HT2 A even 
though this affinity has been proven to be little (Burke, 2002).  However, to our opinion 
escitalopram is the drug of first choice to investigate the serotonergic system by reason 
of its highest selectivity. Whenever comparing results of studies using different 
substances for pharmacological modulation one has to think about the various affinities 
drugs may exhibit.  Being rapidly and nearly completely absorbed after oral single-dose 
administration escitalopram achieves maximal plasma concentrations (Cmax) after 
approximately 3  1.5 hours (Rao, 2007). Based on this fact we started fMRI scanning 
and likewise performance of the stop signal task at the moment we expected to reach 
most likely Cmax. For reasons of control we determined plasma hormone concentrations 
35 
 
(data not presented here) to document an increase of plasma prolactin e.g. as SSRIs 
are known to elevate plasma prolactin concentrations in humans (Attenburrow et al. 
2001). Nevertheless, to be sure that task performance and fMRI scanning were starting 
exactly at time of Cmax continuous monitoring of prolactin plasma level would have been 
desirable and should be done in future studies. We used a dose of 10 mg escitalopram 
consistent with the commonly used dose of 10-20 mg in clinical treatment (Rao, 2007). 
Yet, the dose we administered was lower limit and a higher dose possibly might 
produce effects to a greater extent, resulting in wider or different modulation of brain 
activation patterns or even in effects on task performance. Moreover, there is evidence 
that 5-HT increase following acute administration of SSRIs not only stimulates 
postsynaptic 5-HT receptors but also activates inhibitory 5-HT1A autoreceptors 
producing a reduction of activity in the 5-HT system (Cools et al. 2008). In contrast, 
during long-term treatment autoreceptors are desensitized and 5-HT system activity 
increases. Therefore it is necessary to differ between acute and chronic administration 
of SSRIs. To achieve steady plasma concentrations of escitalopram approximately 7-10 
days of administration are required (Rao, 2007). This is in line with findings from the 
treatment of major depression where escitalopram shows first positive effects on 
symptoms not before 1-2 weeks of continuous administration (Burke, 2002). To secure 
an increase of activity in the 5-HT system chronic administration of escitalopram for at 
least this time period should be used. More research using chronic drug administration 
hence aiming for steady plasma concentrations would provide more definite evidence. 
Although fMRI technique provides a good possibility for investigation of cerebral 
structures and functions it still leaves some uncertainties. For instance, the influence of 
drug administration on general blood flow has to be considered. Activations measured 
in fMRI are direct reflection of the difference between the magnetic properties of 
oxygenated and desoxygenated hemoglobin or BOLD response. But they are 
considered to measure also neural activity indirectly. However, it cannot be eliminated 
that ecsitalopram could produce non-specific effects on blood flow in the brain and 
therefore on BOLD response. We found activations in brain areas that have been 
associated with response inhibition previously in similar studies and also in studies 
using no pharmacological modulation. So we would argue that activations measured in 
our study are not caused by general effects of escitalopram on blood flow. Another 
uncertainty in interpretation of fMRI data is the fact that increase of activity is believed to 
be an indirect measurement of increased neural metabolism. Nevertheless, it has to be 
questioned whether this activity increase reflects neurons being more activated because 
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of better performance. This activity could likewise reflect the recruitment of more cells 
needed to achieve same capacity. Also, fMRI just allows a conclusion on activations. To 
investigate actual activations it would be superior to use PET. However, this method is 
more invasive and as it is connected with radiation it holds more risk for physical health 
of participants consequently. 
 
Conclusions 
In the present study we investigated the effects of SSRI escitalopram on brain 
activations associated with response inhibition. We did not find differences in behavioral 
measures of response inhibition with escitalopram and placebo. Yet, we found 
modulation of brain activation patterns after acute administration of escitalopram during 
a stop signal task. Escitalopram enhanced activations of brain regions that have been 
consistently related to response inhibition, including right OFC and subcortical regions. 
Our results support suggestions of an involvement of 5-HT in neural regulation of 
response inhibition. So far, 5-HT involvement was predominantly discussed for action 
restraint. However, this study shows that 5-HT also influences action cancellation 
through modulation of brain activations. In addition, we found modulating effects of 
serotonin on activations during failed inhibition. In fact, escitalopram enhanced brain 
activations in anterior cingulate supporting its assumed role in error-detection. Our 
results also implicate a fronto-striatal-circuitry for response inhibition in conjunction with 
serotonin. To draw stronger conclusions clearly more research is needed in the field of 
serotonergic modulation and its influence on response inhibition, most notably in 
consideration of the distinction between action restraint and action cancellation.  
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